MEDIAN Technologies Announces Study Award

MEDIAN Technologies, a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected to provide imaging solutions and services in a phase II clinical trial for prostate cancer, sponsored by a global biopharmaceutical company.

“We are very proud of this new success with one of the leading pharmaceutical companies worldwide. This project clearly reinforces our strategy, strengthens our commercial positioning, and further demonstrates the growing interest of major biopharmaceutical groups for our cutting-edge imaging technologies,” said MEDIAN’s Chief Executive Officer, Fredrik Brag.

MEDIAN will provide a wide range of imaging services, from trial-specific imaging procedures and charters to image quality control. MEDIAN will also manage the image independent reviews performed by radiologists using the MEDIAN LMS platform. Based on proprietary image processing algorithms, LMS makes the analysis and interpretation of medical imaging data more reliable, less reader-dependent, and easier to accomplish.

As part of the project, imaging data will be acquired in more than 80 clinical sites located in 18 countries worldwide. Anticipated total enrollment is 250 patients with a forecasted project start by year end.

The amount of the project is estimated at €633,000 (eq. $853,000) for MEDIAN.

This new award builds on the growing success of the company. On March 1, MEDIAN announced the company was selected as an imaging solutions provider for a phase II clinical trials involving more than 100 investigator sites worldwide for a total project amount of €1.4 M (eq. $1.8 M).